Drug Target Review – Issue 2 2020

Posted: 26 May 2020 | | 1 comment

In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.

This issue includes:

    High-throughput screening as a method for discovering new drugs
    Matthew Lloyd, University of Bath
    Antibodies against viral disease: highlighting technologies behind COVID-19 antibody therapy
    Shalom Gurjar, OXGENE
    Neoantigens: presenting new vaccine opportunities in immuno-oncology
    Nikki Withers, Drug Target Review
    Data, data and still more data: the challenges of imaging and analysing 3D cell models
    Margaritha Mysior, University College Dublin
    Jeremy Simpson, University College Dublin
    Application of organoid technology for retinal disease modelling and drug discovery
    Valeria Chichagova, Newcastle University and Newcells Biotech


The rest of this content is restricted - login or subscribe free to access

Screening the future innovations in drug discoveryThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here


One response to “Drug Target Review – Issue 2 2020”

  1. Amit says:

    Very informative article..

Leave a Reply

Your email address will not be published. Required fields are marked *